Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives $3.23 Average PT from Brokerages

Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) have earned a consensus rating of “Hold” from the seven research firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and three have given a buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $3.2250.

A number of research firms have recently issued reports on LXRX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research report on Wednesday, October 8th. Wall Street Zen lowered Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, November 15th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its position in shares of Lexicon Pharmaceuticals by 7.6% during the 3rd quarter. Vanguard Group Inc. now owns 9,521,874 shares of the biopharmaceutical company’s stock worth $12,855,000 after acquiring an additional 670,838 shares in the last quarter. Millennium Management LLC boosted its holdings in shares of Lexicon Pharmaceuticals by 133.1% in the 3rd quarter. Millennium Management LLC now owns 3,830,660 shares of the biopharmaceutical company’s stock valued at $5,171,000 after purchasing an additional 2,187,396 shares in the last quarter. CIBC Bancorp USA Inc. bought a new position in shares of Lexicon Pharmaceuticals in the 3rd quarter valued at $3,240,000. AQR Capital Management LLC bought a new position in shares of Lexicon Pharmaceuticals in the 1st quarter valued at $541,000. Finally, Jacobs Levy Equity Management Inc. acquired a new position in shares of Lexicon Pharmaceuticals during the 3rd quarter worth $935,000. Institutional investors and hedge funds own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Stock Performance

Shares of LXRX opened at $1.17 on Thursday. The stock has a market capitalization of $425.18 million, a price-to-earnings ratio of -6.16 and a beta of 0.71. The firm has a fifty day simple moving average of $1.32 and a 200 day simple moving average of $1.23. The company has a current ratio of 5.64, a quick ratio of 5.63 and a debt-to-equity ratio of 0.47. Lexicon Pharmaceuticals has a 12 month low of $0.28 and a 12 month high of $1.66.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.03. The firm had revenue of $14.18 million for the quarter, compared to analyst estimates of $5.81 million. Lexicon Pharmaceuticals had a negative net margin of 96.77% and a negative return on equity of 52.90%. Research analysts forecast that Lexicon Pharmaceuticals will post -0.66 EPS for the current fiscal year.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.